James Moore: Deals look better for the prey than the predator
Outlook AstraZeneca and Yahoo could be corporate twins. They operate in very different sectors but the problems facing both are remarkably similar, and so are the drugs their respective chief executives have settled upon to treat what ails them.
Both are big, wealthy, cash rich, businesses facing flat or declining revenues while struggling to find replacements for products which are losing either patent protection, or relevance, or both.
Both are now hoping that they can buy their way out of their difficulties. That means paying vastly over the odds for companies which have potential but not much beyond that.
Yahoo's recent acquisition of Tumblr, the blogging site which has a popular product but which doesn't make much out of it, is very much in that category.
Meanwhile Astra, which has been doing much the same thing with a string of biotechnology acquisitions, added to its number yesterday with Omthera Pharmaceuticals, whose speciality is fish oil-derived heart medicines.
Its lead drug has at least completed the final stage of its trials, although it still has to secure final US regulatory approvals, but this is hardly new news.
Even after the announcement of the successful trials, the market valued the company at significantly less than Astra paid for it. The purchase price represents an 88 per cent premium to Omthera's Friday close on the Nasdaq.
It's true that heart drugs are a speciality of AstraZeneca and Omthera's product could be combined with the former's cholesterol treatment Crestor. But, as with Yahoo it's very much could, might, if, maybe. And even if the products of their new playthings are winners, both these giants have to prove they can successfully exploit them. Big companies that buy smaller companies, even in industries that put a premium on innovation like the internet or pharmaceuticals, sometimes struggle to do that.
Their shareholders have to hope that their respective spending binges yield a winner or two, because so far the deals they've done look much better for the prey than the predator – prey that could easily be selling snake oil, rather than fish oil, when it comes to making a return for the predator's shareholders.
Swedish stars ask fans for £195 pledges on crowd-funding website
voicesJust when you thought you could find a man, get married, and have a baby by the age of 35... it turns out you’re too late, says Grace Dent
sportNapoli 2 Arsenal 0: Gunners must now face either Real Madrid, PSG, Bayern Munich, Atletico Madrid or Barcelona in knock-out stages
musicAs Mariah Carey and Noddy Holder rake in the royalties from their classics, why there hasn't been a decent festive hit for 20 years?
theatreAuthor Daniel Rosenthal recalls the mishaps that almost brought the curtain down on the likes of John Gielgud and Diana Rigg
lifeFull of the joys and want to help your fellow man? December isn't the time to do it
lifeAs the Royal Mail plans to phase out deliveries on two wheels, it's no wonder posties are in a spin
techLuke Blackall reports on precision engineered prams and babygros that monitor your child 24-7
- 1 Nelson Mandela memorial: ‘Bogus’ interpreter made mockery of Barack Obama’s tribute
- 2 It’s shameful that our universities have accepted gender segregation under pressure from the most oppressive religious fanatics
- 3 Kenyan politician Mike Sonko left red-faced after photoshopping himself next to Nelson Mandela
- 4 Exeter to Edinburgh and back in a day: How one fresher's lost bet left him facing a 900-mile round trip
- 5 Selfie at funeral: Cameron squeezes in on Obama snap at Mandela memorial
- < Previous
- Next >
iJobs Money & Business
£77099.84 - £96375.26 per annum + Bonus + Benefits : Harrington Starr: My clie...
£45000 - £60000 per annum + Bonus and Package: Harrington Starr: Trading appli...
£50000 - £60000 per annum + BONUS + BENEFITS: Harrington Starr: A leading prov...
£70000 - £90000 per annum + BONUS + BENEFITS: Harrington Starr: A leading mark...